Abstract

Background: Diabetic nephropathy (DN) is the most common microvascular complication of diabetes. Its clinical manifestation is proteinuria, and it is a common cause of renal failure. At present, angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists are often used to treat early DN, and they have good curative effect. On this basis, the treatment of early DN with the combination of astragalus injection is becoming more and more widespread. Therefore, the purpose of this study is to prove the efficacy and safety of astragalus injection combined with Western medicine in the treatment of early DN, and to provide reference value for clinical practice in the future.

Methods: English databases (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese databases (China National Knowledge Infrastructure, Wanfang, VP Information Chinese Journal Service Platform, China Biology Medicine disc) will be searched by computer. From the establishment of the database to February 2021, a randomized controlled trial of astragalus injection combined with Western medicine in the treatment of early DN will be conducted. Two researchers independently evaluate the quality of the included study and extract the data. Included literature is analyzed by Meta with RevMan5.3 software.

Results: In this study, the efficacy and safety of astragalus injection combined with Western medicine in the treatment of early DN are evaluated by serological indexes such as Urinary albumin excretion rates (UAER), serum creatinine and blood urea nitrogen, as well as the adverse reactions of drugs.

Conclusion: This study will provide reliable evidence-based evidence for astragalus injection combined with Western medicine for the treatment of early DN.

OSF Registration number: DOI 10.17605/OSF.IO/A9JGP

Abbreviations: ACEI = angiotensin converting enzyme inhibitor, DN = diabetic nephropathy; UAER = urinary albumin excretion rates.

Keywords: astragalus injection, diabetic nephropathy, meta-analysis, protocol, western medicine treatment

1. Introduction

Diabetic nephropathy (DN) refers to glomerulosclerosis caused by diabetes, which is one of the complications of diabetic systemic microangiopathy. In the early stage of DN [urinary albumin excretion rates (UAER) is 20-200 μg min⁻¹], if there is no timely intervention, the UAER value will increase year by year, and eventually renal failure may occur. Renal failure caused by DN accounts for 13.3% of all dialysis patients. Therefore,
the timely use of drugs for early treatment is of great significance.\cite{2}

A large number of studies\cite{3} believe that reducing urinary protein can delay the progression of DN. And commonly used drugs in clinic are angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists, which have good effects.\cite{4} At present, Astragalus injection combined with Western medicine is widely used in clinical, which has more advantages than using Western medicine alone. The results of several randomized controlled trials show that astragalus injection can reduce urinary protein excretion and improve glucose and lipid metabolism in patients with DN to a certain extent.\cite{5-8} This study included domestic and foreign randomized controlled trials of astragalus injection combined with Western medicine for the treatment of early DN, objectively evaluated its efficacy and safety, and provided an effective basis for clinical promotion.

2. Methods

2.1. Protocol register

This protocol of systematic review and meta-analysis has been drafted under the guidance of the preferred reporting items for systematic reviews and meta-analyses. In addition, it has been registered on open science framework (OSF) (Registration number: DOI 10.17605/OSF.IO/A9JGP).

2.2. Ethics

This study does not involve the privacy of the patients and does not require the approval of the ethics committee and informed consent of the patients.

2.3. Eligibility criteria

2.3.1. Types of studies. We will collect all available randomized controlled trials on astragalus injection combined with Western medicine for the treatment of early DN, unlimited magazine, publication time, and whether to use the blind method. The language is limited to Chinese and English.

2.3.2. Research object. The subjects are diagnosed as diabetic patients, who meet the diagnostic criteria of WHO diabetes in 1999.\cite{9} According to the staging criteria of DN of Mogensen,\cite{10} they are diagnosed as early DN (DN stage III), that is, microalbuminuria. The urine albumin of UAER is 30 to 300 mg at 20 to 200 or 24 hours.

2.3.3. Intervention measures. Control Group: ACEI or angiotensin II receptor blocker + routine therapy (exercise, diet, hypoglycemic, hypotensive, lipid-regulating, etc.).

Treatment Group: Astragalus injection (dosage form, dosage, and usage are not limited) is added on the basis of treatment in the control group.

2.3.4. Outcome index. The main indicators are urinary albumin excretion rate (UAER). The secondary indicators are serum creatinine, blood urea nitrogen, glomerular filtration rate, glycosylated hemoglobin, and adverse drug reactions.

2.4. Exclusion criteria

1. Renal damage caused by other causes.
2. The treatment measures are not consistent with each other.
3. The literature of outcome index can not be obtained.
4. The research in which the full text is not available.
5. The data is wrong or the information is incomplete, but the research that can not be solved by the author can not be solved.
6. For the repeatedly published literature, select the literature with the most comprehensive data and the highest quality.

2.5. Retrieval strategy

The search uses the combination of subject words and free words to search China National Knowledge Infrastructure, Wanfang Database, VP Information Chinese Journal Service Platform, and China Biology Medicine disc with the Chinese words of “Astragalus injection” and “Diabetic Nephropathy,” and in the English database, including PubMed, Embase, Web of Science, and the Cochrane Library, the English search words are “Astragalus Injection” and “diabetic nephropathy”. The search time is from the establishment of the database in February 2021, and randomized controlled trials of astragalus injection combined with Western medicine for the treatment of early DN are collected. Take PubMed as an example, the retrieval strategy is shown in Table 1.

2.6. Data screening and extraction

With reference to the method of screening the literature in the Cochrane Collaborating Network System Reviews Manual 5.0, the 2 researchers use EndNote X7 document management software to download the literature, remove the duplicate literature, and then read the full text to further screen the literature according to the title and abstract. Finally, the required literature is included. The 2 researchers independently screen and extract the literature information, and check with each other. If they encounter differences, they will negotiate and resolve them or ask the third researcher to assist in judgment.

The extraction of the data mainly includes the basic information included in the literature, including the title, the name of the first author, the year of publication, the magazine published and the country in which the study is carried out, the basic information of the subjects, including average age, sex, number of samples, race, severity, etc.; the intervention methods of the treatment group and the control group, including the dose of astragalus injection, the type and usage of Western medicine, etc.; the relevant information of the outcome index. Information about literature quality evaluation includes random grouping method;
allocation hiding method; blind method and so on. The flowchart is used to show the research selection process (Fig. 1).

2.7. Literature quality evaluation

The Cochrane Collaboration’s Tool for assessing risk of bias is used in Review Manager 5.3 software to estimate risk of bias. The evaluation content includes the following 7 parts: ① generation of random sequence; ② allocation concealment of random schemes; ③ blind method was carried out by the subjects and the implementers of the intervention; ④ results the evaluators were blinded; ⑤ integrity of outcome index data; ⑥ selective reporting; ⑦ other aspects of bias. Two researchers will give low risk, unclear, and high risk judgments on the above items, and cross-
check them respectively. If there is any disagreement, it shall be discussed. If no agreement can be reached, it shall be negotiated with the researcher of the third party.

2.8. Statistical analysis
RevMan5.3 software is used for meta-analysis. The dichotomous variable is expressed by the relative ratio. For measurement data, if the measurement tool and measurement unit are consistent, use the weighted mean difference to express, if the measurement tool or measurement unit is inconsistent, then use the standard mean difference as the effective quantity. The heterogeneity between the results is analyzed by \( \chi^2 \) tests, the test level \( \alpha = 0.05 \), combined with \( I^2 \) to judge the heterogeneity, if \( P \geq 0.1, I^2 \leq 50\% \), the heterogeneity is low, and the fixed effect model is used. If \( P < 0.1, I^2 < 50\% \), the source of heterogeneity should be analyzed because there is obvious heterogeneity between studies. The source of heterogeneity should be analyzed. If there is no obvious clinical and methodological heterogeneity, random effect model is used for analysis; if there is obvious clinical heterogeneity and methodological heterogeneity, methods such as subgroup analysis or sensitivity analysis are used. If the clinical heterogeneity is too obvious, it is impossible to carry out subgroup analysis, only descriptive analysis.

2.8.1. Dealing with missing data. If there is missing data in the article, contact the author through email to the relevant information. If the author cannot be contacted, or if the author has lost the relevant data, a descriptive analysis is performed, not a meta-analysis.

2.8.2. Subgroup analysis. According to the different types of Western medicine in the treatment group, the subgroup analysis is carried out; according to the age of the patients, the patients can be divided into 3 subgroups: the young, the middle-aged and the elderly; the subgroup analysis is carried out according to the course of treatment.

2.8.3. Sensitivity analysis. In order to judge the stability of the outcome index, sensitivity analysis is used to analyze each outcome index.

2.8.4. Assessment of reporting biases. If the number of studies included in an outcome indicator is not less than 10, a funnel chart is used to assess publication bias. In addition, Egger and Begg test are used for the evaluation of potential publication bias.

3. Discussion
DN is one of the serious complications of diabetes, and it is a common renal disease in the elderly, which can accumulate renal vessels, glomerulus, renal tubules, and renal interstitium. Its clinical manifestations are proteinuria, edema, hypertension, and nephrotic syndrome. The deterioration of the disease developed into uremia. Clinical commonly used drugs are ACEI, angiotensin II receptor antagonists, and losartan. These drugs can improve glomerular filtration rate, and lower blood glucose and triglyceride in patients with early DN. However, this study also has some limitations. This article only involves Chinese and English literature, and the relevant studies in other languages will be ignored. At the same time, due to the different use of Western medicine in different research institutes, there is a certain clinical heterogeneity between the studies. More high-quality studies are needed to confirm the efficacy of astragalus injection combined with Western medicine for the treatment of early DN.

Author contributions
Data collection: Guojing Li and Bichen Ai.
Funding support: Min Jiang.
Literature retrieval: Guojing Li and Bichen Ai.
Software operating: Weihua Zhang and Xingzhong Feng.
Supervision: Min Jiang.
Writing – original draft: Guojing Li and Bichen Ai.
Writing – review & editing: Guojing Li and Min Jiang.

References
[1] Hong C. Diagnosis and treatment of diabetic nephropathy. Chin J Clin Drug Eval 2008;2:832–932.
[2] Weiyu C, Ziyong T, Shuhong B. Progress in pharmacotherapy of diabetic kidney disease. Clin Med J 2019;12:10–4.
[3] De Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;109:921–7.
[4] Jiuming G. ACEI and ARBs in the treatment of diabetic nephropathy. Drug Eval 2008;5:355–7.
[5] Tingteng Y, Ping L, Minghui Z, et al. Effect of astragalus membranaceus on protein kinase R like endoplasmic reticulum kinase pathway in endoplasmic reticulum stress of diabetic nephropathy mice. Chin J Clin Pharmacol 2019;35:59–61.
[6] Li D, Liu J, Wu Y, et al. Effects of astragalus polysaccharides combined with metformin on glucose and lipid metabolism in liver of aging type 2 diabetic mice. Chin J Inform Tradit Chin Med 2019;4264:47–51.
[7] Qiong Z. Clinical observation of Losartan combined with astragalus injection in the treatment of early diabetic nephropathy. Jilin Med J 2014;35:2146–7.

[8] Lei Z. Clinical observation of high-dose astragalus injection in the treatment of diabetic nephropathy with chronic renal failure. Guide China Med 2014;12:281–2.

[9] WOLF G. Cell cycle regulation in diabetic nephropathy. Kingey Int 2000;58(suppl 77):559–66.

[10] Mogensen CE, Christen CK, Vittinghus E. With emphasis on the stage of incipient diabetic nephropathy diabetes. Diabetes 1983;32:64–78.

[11] Shuang L, Xiewei D, Zhiyi D, et al. Discussion on the pathogenesis of diabetic nephropathy from liver, spleen and kidney. Chin J Integr Tradit Western Nephrol 2020;21:741–2.

[12] Ming L, Cuixia L. Theoretical discussion on the pathogenesis of wind disease caused by qi deficiency. Chin J Basic Med Tradit Chin Med 2020;26:1424–6.

[13] Wenji K. Clinical study of astragalus injection in the treatment of diabetic nephropathy. Pharmacol Clin Chin Materia Medica 2015;31:102–3.

[14] Li Y, Shufang H. The research of the protective value of astragalus membranaceus on the kidneys of diabetic rats. Chin Foreign Med Res 2020;18:6–8.

[15] Aihua X. Study on the effect and value of astragalus injection in the treatment of diabetic nephropathy. Pract Clin J Integr Tradit Chin Western Med 2019;19:77–9.

[16] Gao Y, Lin L, Man Y. Effect of astragalus injection combined with statin on diabetic nephropathy and its effect on microalbuminuria. Contemp Med 2019;25:66–8.

[17] Songju T, Zhinong Y, Hui T. The influence of injection astragalus membraneous on serum and urine TGF-1 in diabetic nephropathy patients and clinical significance. China J Mod Med 2003;13:49–51.

[18] Fu L, Li Y, Lai Y, et al. Effects of Huangqi injection combined with ginseng injection on TGF-1/Smads and BMP-7/Smad 5 signaling pathway in HK-2 cells. Glob Chin Med 2019;12:343–7.

[19] Fang R, Houqian X. Quality evaluation of the report for randomized controlled trials of Huang Qi injection in treating diabetic nephropathy. Western Tradit Chin Med 2013;26:1–1.

[20] Liu S, Deng X. Effect of astragalus injection combined with Valsartan on urine LAP and PCX in treating diabetic nephropathy. Chin J Mod Med 2016;26:102–5.

[21] Xinpeng W, Zengli W, Juntao W. Clinical research on treating diabetes with astragalus injection and TMP injection. Chin J Chin Med 2014;14:318–9.

[22] Yihong S, Fengling Z, Xiuyun D. Clinical observation of telmisartan combined with astragalus injection in the treatment of early diabetic nephropathy. Chin J Integr Tradit Western Nephrol 2014;15:799–800.

[23] Feng Z. Clinical observation of ligustrazine injection combined with astragalus injection in the treatment of early diabetes mellitus complicated with nephropathy. Contemp Med Forum 2014;12:2275–6.